Sectors
ACRV
Acrivon Therapeutics, Inc.
2.09
2 x 1.14
2 x 2.06
bid
ask
+
0.03
1.46%
2 @ 04:00 PM
2.05 -0.04 (1.91%)
| Ytd | -13.28% | |
| 1y | 55.97% |
2.02
day range
2.11
1.27
52 week range
3.56
| Open | 2.04 | Prev Close | 2.06 | Low | 2.02 | High | 2.11 | Mkt Cap | 89.56M |
| Vol | 159.61K | Avg Vol | 401.78K | EPS | -1.92 | P/E | N/A | Forward P/E | -2.31 |
| Beta | 1.85 | Short Ratio | 15.38 | Inst. Own | 75.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 1.81 | 200-d Avg | 1.86 | 1yr Est | 21.11 |
| Income Statement | |||
| Operating Expenses | 18.67M | ||
| Research and Development Expense | 13.84M | ||
| Selling, General and Administrative Expense | 4.82M | ||
| Operating Income | -18.67M | ||
| Net Income | -17.96M | ||
| Net Income Common Stock | -17.96M | ||
| Net Income Common Stock (USD) | -17.96M | ||
| Consolidated Income | -17.96M | ||
| Earnings per Basic Share | -0.43 | ||
| Earnings per Basic Share (USD) | -0.43 | ||
| Earnings per Diluted Share | -0.43 | ||
| Earning Before Interest & Taxes (EBIT) | -17.96M | ||
| Earning Before Interest & Taxes (USD) | -17.96M | ||
| Weighted Average Shares | 41.84M | ||
| Weighted Average Shares Diluted | 41.84M | ||
| Balance Sheet | |||
| Cash and Equivalents | 41.61M | ||
| Cash and Equivalents (USD) | 41.61M | ||
| Investments | 48.54M | ||
| Investments Current | 48.54M | ||
| Current Assets | 91.49M | ||
| Property, Plant & Equipment Net | 6.23M | ||
| Total Assets | 99.09M | ||
| Debt Current | 1.14M | ||
| Total Debt | 2.12M | ||
| Current Liabilities | 11.45M | ||
| Debt Non-Current | 980.00K | ||
| Total Liabilities | 12.43M | ||
| Accumulated Retained Earnings (Deficit) | -311.89M | ||
| Accumulated Other Comprehensive Income | -33.00K | ||
| Shareholders Equity | 86.67M | ||
| Shareholders Equity (USD) | 86.67M | ||
| Assets Non-Current | 7.60M | ||
| Total Debt (USD) | 2.12M | ||
| Liabilities Non-Current | 980.00K | ||
| Trade and Non-Trade Payables | 861.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 681.00K | ||
| Net Cash Flow from Financing | 7.27M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 7.35M | ||
| Capital Expenditure | -87.00K | ||
| Issuance (Purchase) of Equity Shares | 7.31M | ||
| Net Cash Flow from Investing | 14.95M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 15.03M | ||
| Net Cash Flow from Operations | -14.86M | ||
| Share Based Compensation | 2.21M | ||